JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Environmental Analytics
Environmental and financial analysis dashboard for JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY. Industry: MANUFACTURING
Company Overview for JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
Highlights
Showing data for FY2022
Operational Environmental Cost
$51m
Operational Environmental Cost Intensity
1.38%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$32m
Decoupling Rate (2020-2022)
-34%
Adjusted EBITDA
$494m
Adjusted EBITDA Margin
14%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 64.12% | 53.62% | 14.93% | ||
| 0.28% | 0.36% | 0.45% | 0.50% | |
| 89.23% | 54.99% | 25.05% | ||
| 0.49% | 0.73% | 0.93% | 1.11% | |
| $18m | $33m | $51m | $62m | |
| 80.16% | 54.54% | 21.74% | ||
| 0.77% | 1.09% | 1.38% | 1.61% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
14%
Adjusted EBIT Margin
-3.69%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$2,364m | $3,020m | $3,659m | $3,834m | |
| 27.77% | 21.17% | 4.78% | ||
$1,711m | $2,319m | $3,114m | $2,608m | |
| 72.37% | 76.78% | 85.11% | 68.02% | |
$653m | $701m | $545m | $1,226m | |
| 27.63% | 23.22% | 14.89% | 31.98% | |
$375m | $162m | $-85m | $587m | |
| 15.86% | 5.36% | -2.31% | 15.32% | |
| ENVIRONMENTAL COST DATA | ||||
$18m | $33m | $51m | $62m | |
| 0.77% | 1.09% | 1.38% | 1.61% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$635m | $668m | $494m | $1,164m | |
| 26.86% | 22.13% | 13.51% | 30.37% | |
$357m | $129m | $-135m | $526m | |
| 15.09% | 4.28% | -3.69% | 13.71% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.45%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.38%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | IE | $51m | 1.38% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022